1097730-63-6
Chloro(p-cymene)[(1R,2R)-(-)-2-amino-1,2-diphenylethyl(methylsulfonylamido)]ruthenium(II) RuCl(p-cymene)[(R,R)-MsDpen]
CAS: 1097730-63-6
Molecular Formula: C25H26ClN2O2RuS
1097730-63-6 - Names and Identifiers
1097730-63-6 - Physico-chemical Properties
| Molecular Formula | C25H26ClN2O2RuS |
| Molar Mass | 555.08 |
| Appearance | solid |
| Color | yellow-orange |
| Sensitive | air sensitive |
1097730-63-6 - Introduction
Chloro(p-cymene)[(1R,2R)-(-)-2-amino-1,2-diphenylethyl(methylsulfonylamido)]ruthenium(II) RuCl(p-cymene)[(R,R)-MsDpen] is an organometallic complex consisting of (p-methyl ring) rubidium chloride and [(1R,2R)-(-)-2-amino-1,2-diphenylethyl (methanesulfonamide)] rubidium dichloride and rubidium chloride are reacted in p-methyl ring-furan.
The properties of this complex are as follows:
-Appearance: Usually a light yellow to yellow solid.
-Solubility: Soluble in organic solvents, such as dichloromethane, toluene, etc.
-Melting point: Its melting point is usually between 100-150°C.
Its main uses are:
-Catalyst: The compound can be used as a chiral catalyst in organic synthesis, and is commonly used in asymmetric hydrogenation reactions, asymmetric alkylation reactions, etc.
-Drug development: The chiral ligand of this compound can be biologically active, so it can be used for drug development and synthesis.
The method of preparing the complex is generally carried out by an organometallic synthesis strategy. Specifically, (p-methyl ring) rubidium chloride and [(1R,2R)-(-)-2-amino -1, 2-diphenylethyl (methanesulfonamide)] rubidium chloride are first reacted with rubidium chloride in a suitable solvent and heated to an appropriate temperature for reaction, and finally the product is purified by filtration, crystallization and the like.
Regarding the safety information of this compound, due to the lack of specific data, we cannot give detailed safety information. In general, the following safety precautions should be observed when handling organometallic complexes:
-Avoid inhalation, contact with skin and eyes, and ensure operation in a well-ventilated place.
-Use personal protective equipment such as lab gloves, goggles, and lab coats.
-Disposal of waste in a suitable waste collection system.
For specific safe operation, please refer to the MSDS (Chemical Safety Data Sheet) provided by the chemical manufacturer and ensure that a risk assessment is carried out before operation.
The properties of this complex are as follows:
-Appearance: Usually a light yellow to yellow solid.
-Solubility: Soluble in organic solvents, such as dichloromethane, toluene, etc.
-Melting point: Its melting point is usually between 100-150°C.
Its main uses are:
-Catalyst: The compound can be used as a chiral catalyst in organic synthesis, and is commonly used in asymmetric hydrogenation reactions, asymmetric alkylation reactions, etc.
-Drug development: The chiral ligand of this compound can be biologically active, so it can be used for drug development and synthesis.
The method of preparing the complex is generally carried out by an organometallic synthesis strategy. Specifically, (p-methyl ring) rubidium chloride and [(1R,2R)-(-)-2-amino -1, 2-diphenylethyl (methanesulfonamide)] rubidium chloride are first reacted with rubidium chloride in a suitable solvent and heated to an appropriate temperature for reaction, and finally the product is purified by filtration, crystallization and the like.
Regarding the safety information of this compound, due to the lack of specific data, we cannot give detailed safety information. In general, the following safety precautions should be observed when handling organometallic complexes:
-Avoid inhalation, contact with skin and eyes, and ensure operation in a well-ventilated place.
-Use personal protective equipment such as lab gloves, goggles, and lab coats.
-Disposal of waste in a suitable waste collection system.
For specific safe operation, please refer to the MSDS (Chemical Safety Data Sheet) provided by the chemical manufacturer and ensure that a risk assessment is carried out before operation.
Last Update：2024-04-09 02:00:49
